Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study

Xiuxian Huang,Zhengming Li,Zhenwei Zhai,Qiu Wang,Rongyan Wei,Jiacheng Mo,Jianhao Huang,Wensheng Lu

DOI: https://doi.org/10.2147/dmso.s447897

2024-03-07

Diabetes Metabolic Syndrome and Obesity Targets and Therapy

Abstract:Xiuxian Huang, 1, &ast Zhengming Li, 1, &ast Zhenwei Zhai, 1, &ast Qiu Wang, 1 Rongyan Wei, 1 Jiacheng Mo, 2 Jianhao Huang, 1 Wensheng Lu 1, &ast 1 Department of Endocrinology and Metabolism of Guangxi Academy of Medical Sciences, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China; 2 Information Network Center of Guangxi Academy of Medical Sciences, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wensheng Lu, Email Aim: Metabolic dysfunction-related fatty liver disease (MAFLD) is closely related to metabolic disorders. However, the relationship between MAFLD and the prognosis in diabetic foot ulcers (DFUs) remains unclear. This study aimed to explore the association between MAFLD and the risk of major adverse cardiac and cerebral events (MACCEs) in patients with DFUs. Methods: 889 inpatients with DFUs (PEDIS/TEXAS mild and above) were included in this study from 2013 to 2023. All participants were placed into non-MAFLD ( n = 643) and MAFLD ( n = 246) groups and followed up every 6 months for 10.9 years with a median of 63 months through in-person outpatient interviews and family fixed-line telephone visits. The association between MAFLD and the risk of MACCEs was evaluated through Multivariate Cox regression analyses, Stratified analyses and Kaplan-Meier survival analyses. Results: Of the 889 subjects, 214 (24.07%) experienced MACCEs. Multivariate Cox regression analysis showed that MAFLD was independently associated with MACCEs ( P < 0.001), of which with non-fatal myocardial infarction ( P = 0.04), non-fatal stroke ( P = 0.047), coronary artery revascularization ( P = 0.002), heart failure (P = 0.029), and all-cause mortality ( P = 0.021), respectively. The stratified analysis revealed that compared with non-MAFLD (HR=1), DFUs with MAFLD had a 2.64-fold increased risk for MACCEs (P < 0.001; P for interaction = 0.001) in peripheral arterial disease (PAD) subgroup. Kaplan-Meier analysis evidenced that the MAFLD group had a higher cumulative incidence of MACCEs (log-rank, all P < 0.05). Conclusion: MAFLD is a high-risk factor for MACCEs in patients with DFUs. The findings will remind clinicians to pay more attention to MAFLD in patients with DFUs, especially in patients with DFUs combined with PAD as early as possible in clinical practice and adopt timely effective intervention strategies to prevent the occurrence of MACCEs to improve the clinical prognosis in patients with DFUs. Keywords: diabetic foot ulcers, peripheral arterial disease, metabolic dysfunction-associated fatty liver disease, major adverse cardiac and cerebral events At present, China has the highest incidence rate of diabetes in the world, with a prevalence rate of 12.4%, of which about 30% will eventually suffer from diabetes foot ulcers (DFUs). 1 DFUs refer to a foot ulcer, infection, or profound tissue destruction caused by peripheral arterial disease (PAD), lower extremity arterial ischemia, peripheral neuropathy, and deep tissue infection. 2 DFUs are characterized by high morbidity, disability, and mortality caused by severe infection, pulmonary embolism, myocardial infarction, cerebral infarction, heart failure, and surgical amputation. 3 The recurrence rates of DFUs are 40% within a year, 60% within three years, and 65% within five years worldwide. 4 Patients with DFUs have a 2.5 times higher mortality risk than those without DFUs, 5 and the 5-year mortality rate is nearly identical to malignancy. 6 DFUs with a prevalence rate of 8.1%, 31.6% recurrence rate, 5.1% amputation rate, and 14.4% mortality rate in China have seriously threatened public health and brought a huge economic burden to society. 1 Approximately 25% of adults worldwide suffer from metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), which has a significant negative impact on public health and economic development. 7 Recently, an international expert group from 22 countries reached a consensus on naming NAFLD as MAFLD and the diagnostic criteria for MAFLD. The criteria are based on evidence of hepatic steatosis and one of the three conditions listed below: existing overweight or obesity, T2DM or metabolic dysregulation. 7 With this newly revised classification, most DM can be categorized as MAFL -Abstract Truncated-

endocrinology & metabolism